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izxl 1213 150 Women Experience More Cardlac Events Than Men Atter Primary Coronary Angioplasty for 
Acute Myocardlal nfarctlon 
RR. Agar, R. McKay, R. Nasell, A. Pohl, D. Fram, J. Hirsl, R Menneli, 
J. Mllchell, D. Walers, F. Klernan, Har’lford /fospifa/ and fhs Unlw~lfy of 
connmcr/cut &hod af Medlc~n~, 61; USA 
Men and women preesnt differently wllh ncute myocardlal InfarctIon (MI) and 
may have different rosponres IO pemulanODU8 rW~OCUlPrlZ~llon~ 
Mefhadr: To comoare the outcome belween men (n (I 124) and women 
(n 9 83) we mvlewed 187 oonrecullva pnllenls wlth aoute MI treated with 
prlmrry PTCA. Long term lollowup wan avallable on QU?b of patlanta and was 
equal between lha lwo groupa (mean 7 :L 4 monlhs), Qaaellne ehnraclerlatlcs 
were nlmllnr oxcopl (hat women were older (6Q k 13 ve 88 + 11; p *: O,OOl)x 
Rauultr: Man and women did not dillar In the aeda suacesa rata far PTCA 
(Q4% VI QZ%), coronary atentlng (46% va 4896). abalxlmab admlnlstratlon 
(12% M 48%), number 01 veaasls wllh camnary arlsry dlaoase (1 .Q and 2 
per pntlent) and In the e)aatlon tractlon (44 f. 11 va 43 II 10). The lsnglh 01 
hospllal stay tended tn be shorter for man (0 i 0 vs 7.7 i- 6 days; p 9 0.08). 
Men lewa commonly required blood lranalualon (8,QSk vn 3896: p ., O.OOl), 
Tha end polnla of recurrent unatabla anglna (UA) or ru+‘Ibrct,t!an ! ?r&’ 
vassal mvasculan~atlon (TVR) and daaIh m hnapllal a~1 ~~UICII~ tullowup. 
wara nil hioher tar women, 
‘p = 0 Ora, “p I 0 t-11, tp 0 OR comgnfml 10 women 
Ctmcfusran: Dsaplts slmllar bnsallns CharaclenntI~n and tha Rnme lnlllal 
success rats. woman wRh acute) Ml undargalng pnmary PTCA oxpancnce 
more adverne cardiac evenls pout procadum than man. 
Influsncs of Thrombolyala nd Antlplatelet 
Drugs on Myocardlal nfarotlon Patlent 28~Day 
CasaFatall 
r 
Rsnds From 1878 to 1993 In 
Qsrona, Spa n 
r3&gmund~Tharapeu~lc lmpruvemenls such aathmmbolyllc and anbplalolel 
aganls reduced aarly morlallly of myocardlal nlarcllon (MI) pabents In cknlcal 
MaIs. which do not nocessarlly ieflacl mal-llfo hospllal patlent can0 mix. The 
nlm 01 lha study was to analyro e&day case-lalallly bonds botwaen 1976 
and 1883 nmong hospltakzod myocardlal infarctton patlonls in Gerona. Spam. 
nnd reInto them IO changes in pauent characlerl8Ucs and lo thrombolysls and 
nnllplalnlet drug use 
WfhcUs. 2.O53consoculwo pahonls ngod 25-74 years wtth a!~\ Q-wavo 
MI admlttcd to a mlorenco hospllal betwoen 1876 and 1883 wore registemd. 
Four 4.year par&is wem ccmaldered: lR78-81. 1962-65 (pre-Wmmbolylic). 
1888-89 (Wcmbolysls and antiplalolel drugs Introducad) and 1800-93 
(rhromboly8ls and antlplalolol drugs were routinely used). Tho ondpolnt was 
2a.dav case-lalallty 
R~ulfs: 2%day case-latakty decreased 5.4Wyoar between 1876 and 
1893. In a logisttc modal adjusted for comorbldily and severily potential 
conlounders. the 4 periods considered showed a steep docroaso in Iho 
mlabve nsk 01 dymg (see table). Mortality risk mducUon was 34.2% for 
anllplatelel drugs. 24.89. lor lhmmbolysis and 57.8% lor both combined. 
Pon0a Rolnlivo nsh (65% conftaonco tnlelvall 
1978-81 1 
1082-85 cl AR (0 54-l 46) 
198589 0 5R (0 35-o 97) 
1999-93 0 44 (0.26-0.73) 
.- 
CO~~C~US~O~S The magruludo of the short-term benefit of fhror lbotysls and 
anbplatolol drugs In consecullve Q-wave llrst Ml patients is at I.,ast as largo 
as that observed in conlrolled clinical trials 
CK posh ‘SEI . 1022 3143 t 2457 -005 
posl.~nlarcl~on nschaemta pd 52 57 NS 
IRA pa,o”cy I%) 90 80 NS 
delayed PTCA I%) 43 65 NS 
Residual viabikty was slgndr:anlly htgher In gr.1 (66 i 18% vs 38 ! 
210.. p . 0.01). simdarly. recovey was slgmhcanlly greater in thus group al 
dlscharge (53 f 20% vs 16 t 22:.. p . 0.01) and after 6 months (67 : 12 
vs 32 + 12. p < 0.01). 
Conc/usrons: I.v. mfuslon of D started bolero coronary reperluslon seems 
(0 oxorl a beneficial eflocl on lpfarcl SIB% residual myocardlal vlablhty and 
recovery o! regIonal lunchon. Thase prokmmary results will be substanbaled 
by a large tnal on the use of D as adjunctwe therapy In acute myocardlal 
mlarcbon. 
I 1213 152 Carvedllol Prevents Remodelllng In Acute Myocardlal InfarctIon Wlth Left Ventricular 
Dysfunction 
R. Sonior. S.K. Sasu. A. Lahiri. Northwick Park Hospital. Harrow, UK 
Ba&gmund: The surrogate markers 01 romodelling after acute myocardial 
infarction (AMI) are alteration o: LV geomeiry. increases in contralateral wall 
thickness and LV mass, and iniarct expansion. Carvedilol (C) IS a multiple- 
action vasodilating b-blocker which has shown to improve prognosis and LV 
function in congestive heart faikxe (CHF). 
JACC Fchmry I998 
Mef!rods: From a larger randomlsed study 01 C vemus placebo (P) In AMI. 
pts were selected with pre.discharge LVEF of ~45%~ and echocardlography 
was uaod to measure lndlces 01 remodalllng al pre~dlscharge (7-10 days) and 
at 3 months, In addltion. serious cordloc events (death. AMI. hospllallsatlon 
due to unstable angina. CHF and VT) were alao monItored. PIs mcelved 
lntravenuue end oral medlcallon lmmedlalely alter thrombolysie and lhls was 
contlnund for 6 monlhs. 
Resul/s: Analysis of verlttnce showed thal contralateral wall thickness 
(mm) changed from 12.3 k 2.1 to 11.0 f 2.4 wllh C compared to 11.5 f 1.9 
10 12.2 ,I: 1 .B wllh P (p I 0.01): LV mass (gms) changed ftem 235 f 74 to 217 
t 54 wllh C compared to 227 t 50 to 2s2 + QQ with P (p 9 002); 8phetiCity 
index (mlio al long and ahort axln al LV) changad from 1.5Q ,t 0.29 to 1 .B(I 
i 0.20 wllh C compamd to 1,5R t 0.33 to 139 .t 0.19 with P fp Q 0.02); and 
lnlaml nma (sqcm) shangsd ham Q,2 t 3.1 to 9.1 TV 3.1 aompamd to lg.3 t 
3.3 to 13.8 f 4.6 on P (p 9 0,002), Serlour cardiac event6 warn reduced by 
65% In pte on 6 compared to P (p * 0.04). 
Cons/ueiona: The attanuntlon in mmodellmg with carvadilol may eignili~ 
cantly Improve pmgnoals tallowmQ AMl, 
~$iiiij Ftandomlrod Trial of DHtlauam Ourlng Aaua 
Mvoaardlal InfarctIon: BIiacta on Mvocardlal 
Ripwfucilon 
0. Pnrani, C. Cu. A Mailhaa. C. Ballaretla, C Melani. S.L. Chierehla. 
IRCCS H San RafWe~ Warna hafy 
Background In previous expenmonlal studies Diltlazem lD) reduced the do 
gres of stunning and roperfusion InJuly. tlowever. lha matonly Qt cknhxil tnala 
have lallad to show benallt in t&wave myoaard~ol mlarcllon, We evaluaIad 
tha effect al D, admtrvsfered belom coronary reperfusrorr. on inlarct 5vB. 
realdual myocardial viabilib and left ventricular tunclion recavory. 
Methods: From June Q6 to March 97 we studted 95 pattenls (ph) adont- 
ted within 3 hours horn tho onset of symptoms ol AMI. We excluded 54. 15 
bocauao al ST sagmen\ depression, 20 elected to direct PEA. 4 tof card+o- 
gonlc shock. 6 tar conNomdtcalion8 to lhombolys~9, 9 for bradlcardm or AV 
block. The romammg 42 pls wem given fmnt~loaded TPA and imn!edmt+ 
randomized lo receive I.V. 0 (10 mg bolus + 10 mgfl~ lor 3 dsy8) (gmup 
1. 21 ~18) or placebo (gmup 2. 21 pts). All underwent echccardqrarns on 
admisslon. atlet 4 day8 dunng dobulamine test (5-10-20 gammaikg’mtn). 
al discharge and altar 6 months. We cakulated the ctysluncl~on rxora (hy 
pokinosia i 1, akinesla = 2. dlskmesia = 3) on admE8lon and i\s percent 
reduclion aller dobulamme lest ivIabIlity) and at lollow-up (recovery). All ph 
wore continuously monitored (12 leads ST-Surveyor. Mortara Rangonr) for 
lhreo days and underwenl coronary angcugrqqhy v&h n 7 days. PTCA was 
perlormod whonovor residual s1enosls of the inlarcI relaled artery (IRA) was 
more than 60°0 
Flesulffi- On admtisslon. there were no differences In age. sex mlarctton 
site. degree 01 ST-segment olovatton. tlme from onsol 01 symploms and 
dyslunchon score (gr 1 16 t 6. gr 2. 14 I 6. p c NS) Tho table summanre 
Iho results: 
